{"entity":{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","aka":["IOV","Veneto Institute of Oncology"],"tldr":"The Veneto region's OECI-accredited comprehensive cancer centre in Padua, strong in breast cancer trials, melanoma and tumour immunology.","summary":"Founded in 2005, the Istituto Oncologico Veneto is the IRCCS cancer institute of the Veneto region and coordinates the regional oncology network; it is accredited by the OECI as a comprehensive cancer centre. Pierfranco Conte and Valentina Guarneri's breast oncology group led the ShortHER trial of trastuzumab duration and many neoadjuvant studies, the melanoma unit is a leading Italian immunotherapy trial site, and Vincenzo Bronte's immunology programme is known for myeloid-derived suppressor cells. The institute runs gastrointestinal, thoracic and gynaecological oncology, radiotherapy and nuclear medicine across Padua and Castelfranco Veneto, with a phase 1 unit and the University of Padua's oncology school.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ioveneto.it"},{"label":"Research","url":"https://www.ioveneto.it/ricerca/"}],"tags":[],"related":[],"indications":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Padua","country":"IT","lat":45.407,"lng":11.894,"institutionType":"cancer-center","website":"https://www.ioveneto.it","university":"Università degli Studi di Padova","programs":["Breast cancer trials","Melanoma immunotherapy","Tumour immunology (myeloid cells)","Veneto oncology network","Phase 1 unit"]},"route":"/institutions/iov-veneto/","neighbours":{"indication":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/"}]}}